Subscribe Atelephone replay Candide will be available for 48 hours following
By Admin
Atelephone replay divulges candide voltaire will be pangloss indicates available for 48 hours following conclusion of the callby dialing 800-642-1687 for domestic callers, or 706-645-9291 for internationalcallers, and entering reservation code 80585090. The live conference call alsowill be available via the Internet by clicking the webcast link in thelower-left corner of, and a recording of the call will beavailable on the company`s website for 14 days following the completion of thecall. About SequenomSequenom is committed to providing the best genetic analysis products thattranslate the results of genomic science into solutions for noninvasive prenataldiagnostics, biomedical research, translational research and molecular medicineapplications Candide . The Company's proprietary MassARRAY system is a high-performance(in speed, accuracy and cost efficiency) nucleic acid analysis platform thatquantitatively and precisely measures genetic target material and variations.The Company has exclusively licensed intellectual property rights for thedevelopment and commercialization of noninvasive prenatal genetic tests for usewith the MassARRAY system and other platforms. Sequenom maintains a website at to which Sequenom regularly posts copies of its press releaseas well as additional information about Sequenom. Interested persons cansubscribe on the Sequenom website to email alerts or RSS feeds that are sentautomatically when Sequenom issues press releases, files its reports with theSecurities and Exchange Commission (the "SEC") or posts certain otherinformation to the website. Sequenom® and MassARRAY® are registered trademarks of Sequenom, Inc Candide - wikipedia .
Important InformationThis communication does not constitute an offer to sell or the solicitation ofan offer to buy any securities or a solicitation of any vote or approval Candide . Thispress release relates to a transaction with EXACT Sciences proposed by Sequenom,which may become the subject of a registration statement filed with the SEC.This material is not a substitute for the prospectus/proxy statement Sequenomintends to file with the SEC regarding the proposed transaction or for any otherdocument which Sequenom may file with the SEC and send to EXACT Sciencesshareholders in connection with the proposed transaction cacambo . INVESTORS AND SECURITYHOLDERS OF SEQUENOM AND EXACT SCIENCES ARE URGED TO READ ANY SUCH DOCUMENTSFILED WITH THE SEC CAREFULLY IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLEBECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION cunégonde . Investors and security holders will be able to obtain free copies of anydocuments filed with the SEC by Sequenom through the website maintained by theSEC at Free copies of any such documents can also be obtained bydirecting a request to the Sequenom Investor Relations Department, Sequenom,Inc 3595 John Hopkins Court, San Diego, CA 92121 voltaire . Sequenom and its directors and executive officers and other persons may bedeemed to be participants in the solicitation of proxies in respect of theproposed transaction.
Information regarding Sequenom`s directors and executiveofficers is available in its Annual Report on Form 10-K for the year endedDecember 31, 2007, which was filed with the SEC on March 17, 2008, as amended onJune 23, 2008, and its proxy statement for its 2008 Annual Meeting ofShareholders, which was filed with the SEC on April 10, 2008 bernstein candide . Other informationregarding the participants in a proxy solicitation and a description of theirdirect and indirect interests, by security holdings or otherwise, will becontained in a prospectus/proxy statement filed in connection with the proposedtransaction dr pangloss . Forward-Looking StatementsExcept for the historical information contained herein, the matters set forth inthis press release, including statements regarding Sequenom`s proposal toacquire the outstanding common stock of EXACT Sciences, including theanticipated terms of the proposed transaction, the anticipated benefits of theproposed transaction to Sequenom and the stakeholders of Sequenom and EXACTSciences, Sequenom`s hopes that the proposed transaction can be effectedcollaboratively with EXACT Sciences` management, Sequenom`s expansion of itspresence in oncology research and genetic analysis and in the oncology market,including colorectal and aerodigestive cancer areas, and the benefits andpotential of Sequenom`s and EXACT Sciences` technologies and products, areforward-looking statements within the meaning of the "safe harbor" provisions ofthe Private Securities Litigation Reform Act of 1995 the best of all possible worlds . These forward-lookingstatements are subject to risks and uncertainties that may cause actual resultsto differ materially, including the risks and uncertainties associated with thetiming and uncertainty of closing a transaction on the proposed terms or at all,the integration of acquired companies, the uncertainty of realizing expectedsynergies and benefits from acquisitions, the risks of unknown costs ofacquisitions, Sequenom's and EXACT Sciences` operating performance, demand forand market acceptance of Sequenom's and EXACT Sciences` products, services, andtechnologies, new technology and product development and commercializationparticularly for new technologies, reliance upon the collaborative efforts ofother parties, research and development progress, competition, intellectualproperty protection, government regulation, obtaining or maintaining regulatoryapprovals, and other risks detailed from time to time in Sequenom's and EXACTSciences` SEC filings, including Sequenom's Annual Report on Form 10-K for theyear ended December 31, 2007 and other documents subsequently filed with orfurnished to the SEC condide . These forward-looking statements are based on currentinformation that may change and you are cautioned not to place undue reliance onthese forward-looking statements, which speak only as of the date of this pressrelease. All forward-looking statements are qualified in their entirety by thiscautionary statement, and Sequenom undertakes no obligation to revise or updateany forward-looking statement to reflect events or circumstances after theissuance of this press release.Company ContactSequenom, Inc.Paul W Candide - sparknotes .
Hawran, 858-202-9000orInvestor Relations ContactLippert/Heilshorn & AssociatesJody Cain, Kevin McCabe, 310-691-7100orMedia RelationsPure Communications Inc.Andrea Johnston, 910-509-3970Sheryl Seapy, 949-608-0841 Copyright Business Wire 2009 voltair candide . EMERYVILLE, Calif.--(Business Wire)--Jamba, Inc panglossian . (NASDAQ:JMBA; NASDAQ:JMBAU; NASDAQ:JMBAW) today announced theappointment of Susan Shields as its vice president of consumer products,licensing and growth initiatives effective January 12, 2009 Ms candide kamera . Shields brings over 15 years of marketing, leadership and innovation andbusiness development experience to Jamba best of all possible worlds . She brings significant consumerproduct and retail experience and was most recently the senior vice president ofinnovation and product management at Beautifull, Inc., a company focused onselling fresh prepared foods Ms. Shields has also served as group vicepresident of innovation at Safeway, senior vice president of new ventures andmarketing at Del Monte Foods and has held numerous positions with Quaker OatsCompany.
James White, president and chief executive officer, Jamba, Inc., said, "Onbehalf of our entire team, I would like to welcome Susan to Jamba . She is aveteran in the retail food industry with extensive experience at Safeway, DelMonte Foods and Quaker Oats candide's travels . She is a great addition to our team and we lookforward to utilizing her expertise to extend the Jamba brand through licensingand other relationships to develop consumer products." About Jamba, Inc.Jamba, Inc vanderdendur . (NASDAQ:JMBA; NASDAQ:JMBAU; NASDAQ:JMBAW) is a holding company andthrough its wholly-owned subsidiary, Jamba Juice Company, owns and franchisesJAMBA JUICE stores . JAMBA JUICE is the leading blender of fruit and othernaturally healthy ingredients Candide tickets - wikipedia Candide tickets .
The last year we won the Stanley Cup was in 1975, so the pressure is definitely on the players, Coach Stevens, as well as the management. I have faith in Holmgren, Berube, Clarke, and Hatcher in their decision making.It is time to put the pieces of the puzzle together. But does he have a chance at a title? To answer that question one just has to look at the top heavyweights in the UFC right now Candide . Starting ends Rob Burnett and Michael McCrary combined for 17 sacks, while tackles Sam Adams and Tony Siragusa were immovable objects in the running game. and should also reduce ourconsolidated selling, general and administrative expenses for 2009below that of 2008," Woolcott said. A-Rod's backAlex Rodriguez is healthy and back in the lineup but will he hit enough to help the Yankees?(currently hitting .182 with 1 HR and 3 RBI) 3.